Abstract
Quinolones are a very important family of antibacterial agents that are widely prescribed for the treatment of infections in humans. Although the founding members of this drug class had little clinical impact, successive generations include the most active and broad spectrum oral antibacterials currently in use. In contrast to most other anti-infective drugs, quinolones do not kill bacteria by inhibiting a critical cellular process. Rather, they corrupt the activities of two essential enzymes, DNA gyrase and topoisomerase IV, and induce them to kill cells by generating high levels of double-stranded DNA breaks. A second unique aspect of quinolones is their differential ability to target these two enzymes in different bacteria. Depending upon the bacterial species and quinolone employed, either DNA gyrase or topoisomerase IV serves as the primary cytotoxic target of drug action. While this unusual feature initially stymied development of quinolones with high activity against Gram-positive bacteria, it ultimately opened new vistas for the clinical use of this drug class. In addition to the antibacterial quinolones, specific members of this drug family display high activity against eukaryotic type II topoisomerases, as well as cultured mammalian cells and in vivo tumor models. These antineoplastic quinolones represent a potentially important source of new anticancer agents and provide an opportunity to examine drug mechanism across divergent species. Because of the clinical importance of quinolones, this review will discuss the mechanistic basis for drug efficacy and interactions between these compounds and their topoisomerase targets.
Keywords: Type II Topoisomerases, Quinolone Antibacterials, Nalidixic acid, Oxolinic acid, E. Coli DNA Gyrase, Human Topoisomerase, Eukaryotic Topoisomerase II, Etoposide, Amscrine, Antineoplastic Quinolones
Current Pharmaceutical Design
Title: Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde
Volume: 7 Issue: 5
Author(s): Virginia E. Anderson and Neil Osheroff
Affiliation:
Keywords: Type II Topoisomerases, Quinolone Antibacterials, Nalidixic acid, Oxolinic acid, E. Coli DNA Gyrase, Human Topoisomerase, Eukaryotic Topoisomerase II, Etoposide, Amscrine, Antineoplastic Quinolones
Abstract: Quinolones are a very important family of antibacterial agents that are widely prescribed for the treatment of infections in humans. Although the founding members of this drug class had little clinical impact, successive generations include the most active and broad spectrum oral antibacterials currently in use. In contrast to most other anti-infective drugs, quinolones do not kill bacteria by inhibiting a critical cellular process. Rather, they corrupt the activities of two essential enzymes, DNA gyrase and topoisomerase IV, and induce them to kill cells by generating high levels of double-stranded DNA breaks. A second unique aspect of quinolones is their differential ability to target these two enzymes in different bacteria. Depending upon the bacterial species and quinolone employed, either DNA gyrase or topoisomerase IV serves as the primary cytotoxic target of drug action. While this unusual feature initially stymied development of quinolones with high activity against Gram-positive bacteria, it ultimately opened new vistas for the clinical use of this drug class. In addition to the antibacterial quinolones, specific members of this drug family display high activity against eukaryotic type II topoisomerases, as well as cultured mammalian cells and in vivo tumor models. These antineoplastic quinolones represent a potentially important source of new anticancer agents and provide an opportunity to examine drug mechanism across divergent species. Because of the clinical importance of quinolones, this review will discuss the mechanistic basis for drug efficacy and interactions between these compounds and their topoisomerase targets.
Export Options
About this article
Cite this article as:
Anderson E. Virginia and Osheroff Neil, Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde, Current Pharmaceutical Design 2001; 7 (5) . https://dx.doi.org/10.2174/1381612013398013
DOI https://dx.doi.org/10.2174/1381612013398013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NLRP3 Inflammasome Activation Leading to IL-1 – IL-17 Dependent Lung Inflammation and Fibrosis
Current Respiratory Medicine Reviews Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews Regulation of Tumor Immune Microenvironment by Sphingolipids and Lysophosphatidic Acid
Current Drug Targets Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry CD4+CD25+ Regulatory T-Cell Therapy for Allergy, Autoimmune Disease and Transplant Rejection
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets Novel Antitumor Strategies Using Cytokine PEDF for Prostate Cancer Therapy
Current Angiogenesis (Discontinued) Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Vitamin D and Asthma: Scientific Promise and Clinical Reality
Current Respiratory Medicine Reviews Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Functional Role of ADP-Ribosyl-Acceptor Hydrolase 3 in poly(ADPRibose) Polymerase-1 Response to Oxidative Stress
Current Protein & Peptide Science A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
Current Medicinal Chemistry